Results 11 to 20 of about 380,241 (288)

Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer [PDF]

Therapeutic Advances in Medical Oncology, 2020
Background: The introduction of antibodies targeting programmed cell death protein 1 (PD-1) and programmed cell death-ligand 1 (PD-L1) into clinical practice has had a revolutionary effect on cancer treatment.
Bin Zhao, Hong Zhao, Jiaxin Zhao
doaj   +3 more sources

Causal relationships between gut microbiota and programmed cell death protein 1/programmed cell death-ligand 1: A bidirectional Mendelian randomization study

Frontiers in Immunology, 2023
BackgroundMultiple clinical studies have indicated that the gut microbiota influences the effects of immune checkpoint blockade (ICB) therapy comprising PD-1/PD-L1 inhibitors, but the causal relationship is unclear.
Yu-Feng Huang, Wei-Ming Zhang, Zhi-Song Wei, Huan Huang, Qi-Yan Mo, Dan-Li Shi, Lu Han, Yu-Yuan Han, Si-Kai Nong, Guo-Xiang Lin   +9 more
doaj   +3 more sources

Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature

Acta Dermato-Venereologica, 2021
Bullous pemphigoid constitutes a rare dermatological immune-related adverse event of programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors.
Aikaterini Tsiogka, Johann W. Bauer, Aikaterini Patsatsi   +2 more
doaj   +3 more sources

Positive clinical outcomes following therapy with programmed cell death protein 1/programmed cell death ligand 1 inhibitors in neuroendocrine carcinoma of the cervix

Frontiers in Pharmacology, 2022
Neuroendocrine carcinoma of the cervix (NECC) is a highly aggressive and rare gynecological malignancy with a poor prognosis. Despite aggressive local and systemic treatments, there are high rates of locoregional recurrence and distant metastases ...
Rongyu Liu, Rongyu Liu, Xinlin He, Xinlin He, Zhengyu Li, Zhengyu Li   +5 more
doaj   +3 more sources

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. [PDF]

British Journal of Cancer, 2015
Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types ...
Homet Moreno, B, Ribas, A
core   +7 more sources

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis [PDF]

Critical Care, 2018
Debasree Banerjee, Sean Monaghan, Runping Zhao, Thomas Walsh, Amy Palmisciano, Gary S. Phillips, Steven Opal, Mitchell M. Levy   +7 more
doaj   +3 more sources

C2-Symmetrical Terphenyl Derivatives as Small Molecule Inhibitors of Programmed Cell Death 1/Programmed Death Ligand 1 Protein–Protein Interaction

Molecules
The PD-1/PD-L1 complex is an immune checkpoint responsible for regulating the natural immune response, but also allows tumors to escape immune surveillance. Inhibition of the PD-1/PD-L1 axis positively contributes to the efficacy of cancer treatment. The
Joanna Klimek, Oskar Kruc, Joanna Ceklarz, Beata Kamińska, Bogdan Musielak, Robin van der Straat, Alexander Dӧmling, Tad A. Holak, Damian Muszak, Justyna Kalinowska-Tłuścik, Łukasz Skalniak, Ewa Surmiak   +11 more
doaj   +6 more sources

Corrigendum: Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1

Chinese Medical Journal, 2021
doaj   +2 more sources

The analgesic effect of programmed cell death protein-1. [PDF]

Korean J Pain, 2023
Park JY.
europepmc   +3 more sources

Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction [PDF]

Journal of Medicinal Chemistry, 2021
We describe a new class of potent PD-L1/PD-1 inhibitors based on a terphenyl scaffold that is derived from the rigidified biphenyl-inspired structure. Using in silico docking, we designed and then experimentally demonstrated the effectiveness of the terphenyl-based scaffolds in inhibiting PD-1/PD-L1 complex formation using various biophysical and ...
Damian Muszak, Ewa Surmiak, Jacek Plewka, Katarzyna Magiera-Mularz, Justyna Kocik-Krol, Bogdan Musielak, Dominik Sala, Radoslaw Kitel, Malgorzata Stec, Kazimierz Weglarczyk, Maciej Siedlar, Alexander Dömling, Lukasz Skalniak, Tad A. Holak   +13 more
openaire   +5 more sources